adamantane has been researched along with exenatide in 56 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (41.07) | 29.6817 |
| 2010's | 31 (55.36) | 24.3611 |
| 2020's | 2 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Berenbeim, DM; Gilkin, RJ; Gleeson, JM | 1 |
| Edelman, SV | 1 |
| Lebovitz, H | 1 |
| Choukem, SP; Gautier, JF | 1 |
| Drucker, DJ; Nauck, MA | 1 |
| Mikhail, N | 2 |
| Winkler, G | 1 |
| Klein, HH; Meier, JJ; Schmidt, WE | 1 |
| Scheen, AJ | 1 |
| Amori, RE; Lau, J; Pittas, AG | 1 |
| Ahrén, B | 2 |
| Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S | 1 |
| Davidson, JA; Gross, JL; Parente, EB | 1 |
| Bosi, E; Lucotti, P; Monti, L; Piatti, PM; Setola, E | 1 |
| Seissler, J | 1 |
| Siddiqui, NI | 1 |
| Nicolucci, A; Rossi, MC | 1 |
| Gallwitz, B | 1 |
| Miuchi, M; Miyagawa, J; Nanba, M | 1 |
| Freeman, JS | 1 |
| Bilo, HJ; Goudswaard, AN; Houweling, ST; Kleefstra, N; Kooy, A; van Hateren, KJ; Verhoeven, S | 1 |
| Buikema, H; de Boer, RA; Oeseburg, H; Silljé, HH; van der Harst, P; van Gilst, WH | 1 |
| Guerci, B; Halter, C | 1 |
| Unger, J | 1 |
| Kuritzky, L | 1 |
| Fakhoury, WK; Lereun, C; Wright, D | 1 |
| Svec, F | 1 |
| Clar, C; Cummins, E; Marien, M; Philip, S; Richter, B; Royle, P; Waugh, N | 1 |
| Garber, AJ | 1 |
| Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 5 |
| Boudes, P; Viereck, C | 1 |
| Jellinger, PS | 1 |
| Bourdel-Marchasson, I; Dejager, S; Schweizer, A | 1 |
| Avogaro, A; de Kreutzenberg, SV; Fadini, GP; Gjini, R | 1 |
| Jermendy, G | 1 |
| Frier, BM; Inkster, B; Zammitt, NN | 1 |
| Ishikawa, M; Yamada, Y | 1 |
| Asahara, S; Bartolome, A; Etoh, H; Fuchita, M; Hashimoto, N; Hosooka, T; Inoue, H; Kanno, A; Kido, Y; Koyanagi-Kimura, M; Matsuda, T; Mieda, Y; Seino, S; Shimizu, S; Takahashi, H; Teruyama, K | 1 |
| Tibaldi, JM | 1 |
| Bergholm, AM; Brodie, T; Chadwick, KD; Graziano, MJ; LaCerte, C; Mangipudy, RS; Parkes, D; Reilly, TP; Roy, D; Tatarkiewicz, K | 1 |
| Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP | 1 |
| Jütte, H; Meier, J; Montanya, E; Nauck, M; Schmidt, W; Tannapfel, A; Ueberberg, S; Uhl, W | 1 |
| Mudher Mikhael, E | 1 |
| Hemmingsen, B; Metzendorf, MI; Richter, B; Sonne, DP | 1 |
| Burkey, B; Duttaroy, A; Hu, J; Kawamori, D; Kulkarni, RN; Liew, CW; Morioka, T; Shirakawa, J | 1 |
| Kimura, K; Takayanagi, R; Uchida, T; Yamada, Y | 1 |
| Liu, L; Wang, DW; Wang, K; Wang, P; Wang, W; Wen, Z; Wu, L | 1 |
| Azoulay, L; Bouganim, N; Platt, RW; Rouette, J; Yin, H; Yu, OHY | 1 |
| Bermudez Saint Andre, K; Coverdale, S; Dursteler, A; Gutierrez, AD; Hamidi, V; Miller Iii, C; Riggs, K; Taegtmeyer, H; Wang, H; Westby, C; Zhu, L | 1 |
32 review(s) available for adamantane and exenatide
| Article | Year |
|---|---|
Incretin mimetics: promising new therapeutic options in the treatment of type 2 diabetes.
Topics: Adamantane; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Peptides; Pyrrolidines; Venoms | 2005 |
Incretins: what does the future hold?
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Exenatide; Glucagon-Like Peptide 1; Humans; Liraglutide; Nitriles; Peptides; Protease Inhibitors; Pyrrolidines; Venoms; Vildagliptin | 2005 |
Diabetes: assessing the pipeline.
Topics: Adamantane; Alkanesulfonates; Amyloid; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exenatide; Glycine; Humans; Hypoglycemic Agents; Indoles; Islet Amyloid Polypeptide; Maleimides; Nitriles; Oxazoles; Peptides; Phenylpropionates; Piperidines; PPAR alpha; PPAR gamma; Protein Kinase C; Pyrazoles; Pyrrolidines; Receptor, Cannabinoid, CB1; Receptors, Glucagon; Rimonabant; Venoms; Vildagliptin | 2006 |
How do different GLP-1 mimetics differ in their actions?
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrrolidines; Venoms; Vildagliptin | 2006 |
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2006 |
Exenatide: a novel approach for treatment of type 2 diabetes.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Exenatide; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Humans; Hypoglycemic Agents; Insulin; Nitriles; Peptides; Pyrrolidines; Treatment Outcome; Venoms; Vildagliptin | 2006 |
[Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Insulin Resistance; Intestinal Mucosa; Nitriles; Peptide Hormones; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
[New concepts in the treatment of type 2 diabetes].
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Nitriles; Peptides; Piperidines; Pyrazines; Pyrazoles; Pyrrolidines; Rimonabant; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Hypoglycemic Agents; Incretins; Islets of Langerhans; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Topics: Adamantane; Body Weight; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nausea; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Vomiting | 2008 |
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Postprandial Period; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Incretin-based therapies in type 2 diabetes: a review of clinical results.
Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
[The value of incretin based therapies].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
[Incretin related agents for treatment of diabetes mellitus].
Topics: Adamantane; Diabetes Mellitus; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glutaminase; Homeostasis; Humans; Hypoglycemic Agents; Incretins; Intracellular Signaling Peptides and Proteins; Peptides; Pyrazines; Signal Transduction; Sitagliptin Phosphate; Triazoles; Venoms | 2009 |
[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2010 |
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2010 |
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Weight Loss | 2010 |
Incretin physiology and its role in type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Topics: Adamantane; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Nitriles; Peptides; Pyrazines; Pyrrolidines; Quality of Life; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; State Medicine; Thiazolidinediones; Triazoles; United Kingdom; Venoms; Vildagliptin | 2010 |
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Liraglutide; Managed Care Programs; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
Drug-induced hypoglycaemia in type 2 diabetes.
Topics: Adamantane; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Peptides; Pharmacogenetics; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms | 2012 |
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide-1 Receptor; Glucosides; Holidays; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Liraglutide; Nitriles; Peptides; Pyrrolidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Venoms; Vildagliptin | 2016 |
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Nitriles; Peptides; Pyrrolidines; Randomized Controlled Trials as Topic; Risk Factors; Venoms; Vildagliptin | 2017 |
2 trial(s) available for adamantane and exenatide
| Article | Year |
|---|---|
The metabolic syndrome influences the response to incretin-based therapies.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Male; Metabolic Syndrome; Middle Aged; Nitriles; Peptides; Prognosis; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2011 |
Acute Exenatide Therapy Attenuates Postprandial Vasodilation in Humans with Prediabetes: A Randomized Controlled Trial.
Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; Cross-Over Studies; Dietary Fats; Dipeptides; Double-Blind Method; Exenatide; Female; Forearm; Humans; Incretins; Insulin; Lipids; Male; Middle Aged; Obesity; Postprandial Period; Prediabetic State; Texas; Time Factors; Treatment Outcome; Vasodilation | 2020 |
22 other study(ies) available for adamantane and exenatide
| Article | Year |
|---|---|
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
Topics: Adamantane; Animals; Appetite; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
[Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Nitriles; Peptides; Pyrrolidines; Receptors, Glucagon; Treatment Outcome; Venoms; Vildagliptin | 2007 |
Three new drugs for type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2008 |
[Future therapeutic options and their indications: transplantation and the possibilities of regenerative therapy for diabetes type 1].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 1; Exenatide; Humans; Insulin-Secreting Cells; Islets of Langerhans; Islets of Langerhans Transplantation; Mice; Nitriles; Peptides; Pyrazines; Pyrrolidines; Regeneration; Sitagliptin Phosphate; Stem Cell Transplantation; Transplantation, Heterologous; Triazoles; Venoms; Vildagliptin | 2008 |
Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.
Topics: Adamantane; Animals; Cells, Cultured; Cellular Senescence; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Drug; Endothelial Cells; Enzyme Activation; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Heme Oxygenase-1; Humans; Hydrogen Peroxide; Hypoglycemic Agents; Male; NAD(P)H Dehydrogenase (Quinone); Nitriles; Oxidants; Oxidative Stress; Peptides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrrolidines; Rats; Rats, Zucker; Reactive Oxygen Species; Receptors, Glucagon; Signal Transduction; Venoms; Vildagliptin | 2010 |
[New hypoglycemic agents in type 2 diabetes].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2010 |
Choosing among the incretin agents and why it matters.
Topics: Adamantane; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Lipids; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Introduction.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2010 |
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin | 2011 |
[Therapeutic use and adverse events of incretin-related drugs].
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2012 |
DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice.
Topics: Adamantane; Animals; Blood Glucose; CCAAT-Enhancer-Binding Protein-beta; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Endoplasmic Reticulum Stress; Exenatide; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Hyperglycemia; Insulin; Insulin-Secreting Cells; Leupeptins; Mice; Mice, Transgenic; Nitriles; Peptides; Pyrrolidines; Venoms; Vildagliptin | 2012 |
The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.
Topics: Adamantane; Animals; Diabetes Mellitus, Experimental; Dipeptides; Dogs; Exenatide; Glucagon-Like Peptide 1; Haplorhini; Injections, Subcutaneous; Maximum Tolerated Dose; Mice; Organ Size; Pancreas; Peptides; Rats; Venoms | 2014 |
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2014 |
Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.
Topics: Acinar Cells; Adamantane; Adenocarcinoma; Adult; Aged; Carcinoma in Situ; Case-Control Studies; Cystadenoma; Diabetes Mellitus, Type 2; Digestive System Surgical Procedures; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Secreting Cells; Humans; Incretins; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Middle Aged; Neuroendocrine Tumors; Nitriles; Organ Size; Pancreas; Pancreas, Exocrine; Pancreatic Neoplasms; Pancreatitis, Chronic; Peptides; Pyrrolidines; Sitagliptin Phosphate; Tissue Donors; Venoms; Vildagliptin | 2016 |
GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in βIRKO mice.
Topics: Adamantane; Animals; Cell Proliferation; Cyclin A; Cyclin D; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Insulin; Insulin-Secreting Cells; Mice; Mice, Knockout; Nitriles; Peptides; Phosphorylation; Pyrrolidines; Receptor, Insulin; Signal Transduction; Venoms; Vildagliptin | 2017 |
Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Exenatide; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Ligands; Liraglutide; Models, Molecular; Molecular Targeted Therapy; Nitriles; Peptides; Piperidines; Pyrrolidines; Reproducibility of Results; Sitagliptin Phosphate; Uracil; Venoms; Vildagliptin | 2018 |
Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway.
Topics: Adamantane; Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Dipeptides; Exenatide; Glucagon-Like Peptide 1; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR alpha | 2018 |
Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.
Topics: Adamantane; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incidence; Incretins; Linagliptin; Liraglutide; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Risk Factors; Sitagliptin Phosphate; Smoking | 2020 |